Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Allison Brashear. (2005) The safety and tolerability of botulinum toxins for the treatment of cervical dystonia. Expert Opinion on Drug Safety 4:2, pages 241-249.
Read now
Read now
Gulnoz S. Dolimbek, Behzod Z. Dolimbek, K. Roger Aoki & M. Zouhair Atassi. (2005) Mapping of the Antibody and T Cell Recognition Profiles of the HN Domain (Residues 449–859) of the Heavy Chain of Botulinum Neurotoxin A in Two High-Responder Mouse Strains. Immunological Investigations 34:2, pages 119-142.
Read now
Read now
Jack Schim. (2004) Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients. Current Medical Research and Opinion 20:1, pages 49-53.
Read now
Read now
Jonathan P Gladstone & David W Dodick. (2003) Current and emerging treatment options for migraine and other primary headache disorders. Expert Review of Neurotherapeutics 3:6, pages 845-872.
Read now
Read now
AN Nitu, R Wallihan, V Skljarevski & NM Ramadan. (2003) Emerging trends in the pharmacotherapy of chronic pain. Expert Opinion on Investigational Drugs 12:4, pages 545-559.
Read now
Read now
Articles from other publishers (32)
O. N. Egorova, B. S. Belov & E. G. Sazhina. (2021) Use of botulinum toxin type A in rheumatic diseases. Modern Rheumatology Journal 15:5, pages 108-113.
Crossref
Crossref
Min Hou, Haiyan Xing, Yongqing Cai, Bin Li, Xianfeng Wang, Pan Li, Xiaolin Hu & Jianhong Chen. (2017) The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis. The Journal of Headache and Pain 18:1.
Crossref
Crossref
Maria Jenelyn M Alviar, Tom Hale & Monalisa Lim-Dungca. (2016) Pharmacologic interventions for treating phantom limb pain. Cochrane Database of Systematic Reviews 2020:8.
Crossref
Crossref
M. Zouhair Atassi, Masooma Naqvi, Behzod Z. Dolimbek & K. Roger Aoki. (2014) Reduction of established antibody responses against botulinum neurotoxin A by synthetic monomethoxypolyethylene glycol peptide conjugates. Journal of Neuroimmunology 272:1-2, pages 29-34.
Crossref
Crossref
Behzod Z. Dolimbek, Lance E. Steward, K. Roger Aoki & M. Zouhair Atassi. (2011) Location of the Synaptosome-Binding Regions on Botulinum Neurotoxin B. Biochemistry 51:1, pages 316-328.
Crossref
Crossref
M. Zouhair Atassi, Behzod Z. Dolimbek, Joseph Jankovic, Lance E. Steward & K. Roger Aoki. (2011) Regions of botulinum neurotoxin A light chain recognized by human anti-toxin antibodies from cervical dystonia patients immunoresistant to toxin treatment. The antigenic structure of the active toxin recognized by human antibodies. Immunobiology 216:7, pages 782-792.
Crossref
Crossref
J.C. Torres Huerta, J.R. Hernández Santos, E.M. Ortiz Ramírez & S. Tenopala Villegas. (2010) Toxina botulínica tipo A para el manejo del dolor en pacientes con síndrome de dolor miofascial crónico. Revista de la Sociedad Española del Dolor 17:1, pages 22-27.
Crossref
Crossref
M. Zouhair Atassi. (2009) Immune recognition of BoNTs A and B: How anti-toxin antibodies that bind to the heavy chain obstruct toxin action. Toxicon 54:5, pages 600-613.
Crossref
Crossref
M. Zouhair Atassi & K. Roger Aoki. 2009. Botulinum Toxin. Botulinum Toxin
53
76.e8
.
Angelo SghirlanzoniGennaro Bussone & Domenico D’Amico. 2010. Terapia delle malattie neurologiche. Terapia delle malattie neurologiche
217
248
.
Behzod Z. Dolimbek, Lance E. Steward, K. Roger Aoki & M. Zouhair Atassi. (2008) Immune recognition of botulinum neurotoxin B: Antibody-binding regions on the heavy chain of the toxin. Molecular Immunology 45:4, pages 910-924.
Crossref
Crossref
Roberto Casale & Valeria Tugnoli. (2008) Botulinum Toxin for Pain. Drugs in R & D 9:1, pages 11-27.
Crossref
Crossref
Tracy DePuy, Rick Howard, Kevin Keegan, David Wilson, Joanne Kramer, James L. Cook & Martin K. Childers. (2007) Effects of Intra-articular Botulinum Toxin Type A in an Equine Model of Acute Synovitis. American Journal of Physical Medicine & Rehabilitation 86:10, pages 777-783.
Crossref
Crossref
Valeria Tugnoli, Jay Guido Capone, Roberto Eleopra, Rocco Quatrale, Mariachiara Sensi, Ernesto Gastaldo, Maria Rosaria Tola & Pierangelo Geppetti. (2007) Botulinum Toxin type A reduces capsaicin-evoked pain and neurogenic vasodilatation in human skin. Pain 130:1, pages 76-83.
Crossref
Crossref
M. Zouhair Atassi, Behzod Z. Dolimbek, Philip Deitiker, Joseph Jankovic & K. Roger Aoki. (2006) A peptide‐based immunoassay for antibodies against botulinum neurotoxin A. Journal of Molecular Recognition 20:1, pages 15-21.
Crossref
Crossref
Parisa Gazerani, Camilla Staahl, Asbjøn M. Drewes & Lars Arendt-Nielsen. (2006) The effects of Botulinum Toxin type A on capsaicin-evoked pain, flare, and secondary hyperalgesia in an experimental human model of trigeminal sensitization. Pain 122:3, pages 315-325.
Crossref
Crossref
Takahiro Maruta, Behzod Z. Dolimbek, K. Roger Aoki & M. Zouhair Atassi. (2006) Inhibition by human sera of botulinum neurotoxin-A binding to synaptosomes: A new assay for blocking and non-blocking antibodies. Journal of Neuroscience Methods 151:2, pages 90-96.
Crossref
Crossref
Christine M. Cheng, Jennifer S. Chen & Rosalie P. Patel. (2006) Unlabeled uses of botulinum toxins: A review, part 1. American Journal of Health-System Pharmacy 63:2, pages 145-152.
Crossref
Crossref
Roongroj Bhidayasiri & Daniel D. Truong. (2005) Expanding use of botulinum toxin. Journal of the Neurological Sciences 235:1-2, pages 1-9.
Crossref
Crossref
S. Raj Sundaraj, Paul Ponciano, Charlotte Johnstone, Faiz Noore & Maria Castro. (2004) Treatment of Chronic Refractory Intractable Headache with Botulinum Toxin Type A: A Retrospective Study. Pain Practice 4:3, pages 229-234.
Crossref
Crossref
Stefan Evers. (2004) Botulinum toxin and the management of chronic headaches. Current Opinion in Otolaryngology & Head and Neck Surgery 12:3, pages 197-203.
Crossref
Crossref
Arnold William Klein. (2004) The Therapeutic Potential of Botulinum Toxin. Dermatologic Surgery 30:3, pages 452-455.
Crossref
Crossref
ARNOLD WILLIAM KLEIN. (2004) The Therapeutic Potential of Botulinum Toxin. Dermatologic Surgery 30:3, pages 452-455.
Crossref
Crossref
Carla Cordivari, V. Peter Misra, Santiago Catania & Andrew J. Lees. (2004) New therapeutic indications for botulinum toxins. Movement Disorders 19:S8, pages S157-S161.
Crossref
Crossref
Avi AshkenaziStephen D. Silberstein. (2004) Botulinum Toxin and Other New Approaches to Migraine Therapy. Annual Review of Medicine 55:1, pages 505-518.
Crossref
Crossref
WG Ondo, KD Vuong & HS Derman. (2016) Botulinum Toxin a for Chronic Daily Headache: A Randomized, Placebo-Controlled, Parallel Design Study. Cephalalgia 24:1, pages 60-65.
Crossref
Crossref
Minglei Cui, Sid Khanijou, John Rubino & Kei Roger Aoki. (2004) Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain 107:1, pages 125-133.
Crossref
Crossref
Paul Winner. (2003) Botulinum toxins in the treatment of migraine and tension-type headaches. Physical Medicine and Rehabilitation Clinics of North America 14:4, pages 885-899.
Crossref
Crossref
K. Roger Aoki. (2003) Evidence for Antinociceptive Activity of Botulinum Toxin Type A in Pain Management. Headache: The Journal of Head and Face Pain 43:s1, pages 9-15.
Crossref
Crossref
Avi Ashkenazi & Stephen D. Silberstein. (2003) The evolving management of migraine. Current Opinion in Neurology 16:3, pages 341-345.
Crossref
Crossref
Stefan Evers. (2003) Is there a role for botulinum toxin in the treatment of migraine?. Current Pain and Headache Reports 7:3, pages 229-234.
Crossref
Crossref
. (2002) Treatment of Migraine. New England Journal of Medicine 347:10, pages 764-766.
Crossref
Crossref